Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Mcdonald Capital Investors Inc. CA

Mcdonald Capital Investors Inc. CA reduced its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 136,453 shares of the biopharmaceutical company’s stock after selling 2,746 shares during the period. Regeneron Pharmaceuticals comprises about 8.8% of Mcdonald Capital Investors Inc. CA’s investment portfolio, making the stock its 4th biggest position. Mcdonald Capital Investors Inc. CA’s holdings in Regeneron Pharmaceuticals were worth $143,445,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. International Assets Investment Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 86,013.3% during the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after acquiring an additional 879,916 shares during the period. Capital International Investors grew its holdings in shares of Regeneron Pharmaceuticals by 7.3% in the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after purchasing an additional 213,038 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Regeneron Pharmaceuticals by 25.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock worth $868,757,000 after purchasing an additional 184,561 shares in the last quarter. TD Asset Management Inc lifted its holdings in Regeneron Pharmaceuticals by 162.9% during the 1st quarter. TD Asset Management Inc now owns 269,511 shares of the biopharmaceutical company’s stock valued at $259,402,000 after purchasing an additional 166,998 shares during the last quarter. Finally, Swedbank AB bought a new position in Regeneron Pharmaceuticals during the 1st quarter valued at about $129,257,000. Institutional investors own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 1.5 %

Shares of NASDAQ REGN opened at $816.65 on Thursday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $783.57 and a 52-week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The stock has a market cap of $90.03 billion, a P/E ratio of 20.21, a P/E/G ratio of 3.17 and a beta of 0.15. The firm has a 50 day moving average price of $1,035.92 and a 200 day moving average price of $1,038.36.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Oppenheimer decreased their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research report on Wednesday. Leerink Partners reiterated a “market perform” rating and set a $1,077.00 target price (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Cantor Fitzgerald reissued a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Guggenheim boosted their price objective on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Finally, Leerink Partnrs lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. One analyst has rated the stock with a sell rating, four have given a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,092.62.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.